Y-Biologics, Inc. (KOSDAQ:338840)
South Korea · Delayed Price · Currency is KRW 18,210
-1,030 (-5.35%)
At close: May 20, 2026
Y-Biologics Company Description
Y-Biologics, Inc., an antibody therapeutics development company, engages in the research and development of immuno-oncology drugs and antibody drugs.
The company develops YBL-006, a PD-1 immune-oncology agent that is phase 1 clinical stage for the treatment of solid tumor.
It also develops immunoregulatory monoclonal antibodies, such as YBL-011 and AR062 for the treatment of solid cancers; AR166, AR169, and AR170 for solid cancers; and AR153, a pH-dependent antibody for the treatment of solid cancer.
Y-Biologics, Inc. was incorporated in 2007 and is headquartered in Daejeon, South Korea.
Y-Biologics, Inc.
| Country | South Korea |
| Founded | 2007 |
| CEO | Young Woo Park |
Contact Details
Address: #715-B, 17 Techno 4-ro Daejeon South Korea | |
| Phone | 82 4 2867 9971 |
Stock Details
| Ticker Symbol | 338840 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Young Woo Park | Chief Executive Officer |
| Yeon Kyung Lee | Chief Financial Officer |